Global Vector-Based RNAi Market
Global Vector-Based RNAi Market

Vector-Based RNAi Comprehensive Study by Type (SiRNA Design, SiRNA Vectors, Custom siRNA Construction), Application (Oncology, Ocular Disorders, Hepatitis B and C, Autoimmune Hepatitis, Therapeutics, Respiratory Disorders, Neurological Disorders, Other Therapeutics), End-users (Hospitals, Specialty Clinics) Players and Region - Global Market Outlook to 2026

Vector-Based RNAi Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 236 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Vector-Based RNAi Market?

Vector-based RNAi allows to regulate gene inhibition with inducible RNAi expression, control gene expression in vivo with tissue-specific promoters, and select for a pure population of cells stably expressing an RNAi sequence. The factors such as High Demand for Molecular Diagnostics Especially in Cancer, Increased Prevalence of Cancer Disease and Growth in the Healthcare Infrastructure in Developing Regions are the driving factors for the global Vector-Based RNAi market. In addition, Technological Advancements in Medical Science also fueling market growth. However, Stringent FDA Approval Process and HIgh Research and Development Investment may hamper the market growth.

The market study is being classified by Type (siRNA Design, siRNA Vectors and Custom siRNA Construction), by Application (Oncology, Ocular Disorders, Hepatitis B and C, Autoimmune Hepatitis, Therapeutics, Respiratory Disorders, Neurological Disorders and Other Therapeutics) and major geographies with country level break-up.

Merck & Co., Inc. (United States), Phio Pharmaceuticals Inc. (United States), Quark Pharmaceuticals, Inc. (Israel), Thermo Fisher Scientific (United States), Silence Therapeutics (United Kingdom), Qiagen NV (Germany), Ionis Pharmaceuticals (United States), Dicerna Pharmaceuticals (United States), Arrowhead Pharmaceuticals, Inc. (United States), Arcturus Therapeutics (United States) and Alnylam Pharmaceuticals (United States) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Vector-Based RNAi market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Vector-Based RNAi market by Type, Application and Region.

On the basis of geography, the market of Vector-Based RNAi has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • High Demand for Molecular Diagnostics Especially in Cancer
  • Increased Prevalence of Cancer Disease
  • Growth in the Healthcare Infrastructure in Developing Regions

Market Trend
  • Increased Research and Development Activities
  • Technological Advancements in The Medical Science

Restraints
  • Stringent FDA Approval Process

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Increased Government Funding for Healthcare

Challenges
  • HIgh Research and Development Investment





Key Target Audience
Vector-Based RNAi Technology Providers, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • siRNA Design
  • siRNA Vectors
  • Custom siRNA Construction
By Application
  • Oncology
  • Ocular Disorders
  • Hepatitis B and C
  • Autoimmune Hepatitis
  • Therapeutics
  • Respiratory Disorders
  • Neurological Disorders
  • Other Therapeutics
By End-users
  • Hospitals
  • Specialty Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Demand for Molecular Diagnostics Especially in Cancer
      • 3.2.2. Increased Prevalence of Cancer Disease
      • 3.2.3. Growth in the Healthcare Infrastructure in Developing Regions
    • 3.3. Market Challenges
      • 3.3.1. HIgh Research and Development Investment
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
      • 3.4.2. Technological Advancements in The Medical Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Vector-Based RNAi, by Type, Application, End-users and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Vector-Based RNAi (Value)
      • 5.2.1. Global Vector-Based RNAi by: Type (Value)
        • 5.2.1.1. SiRNA Design
        • 5.2.1.2. SiRNA Vectors
        • 5.2.1.3. Custom siRNA Construction
      • 5.2.2. Global Vector-Based RNAi by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Ocular Disorders
        • 5.2.2.3. Hepatitis B and C
        • 5.2.2.4. Autoimmune Hepatitis
        • 5.2.2.5. Therapeutics
        • 5.2.2.6. Respiratory Disorders
        • 5.2.2.7. Neurological Disorders
        • 5.2.2.8. Other Therapeutics
      • 5.2.3. Global Vector-Based RNAi by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
      • 5.2.4. Global Vector-Based RNAi Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Vector-Based RNAi: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Phio Pharmaceuticals Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Quark Pharmaceuticals, Inc. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher Scientific (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Silence Therapeutics (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Qiagen NV (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ionis Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Dicerna Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Arrowhead Pharmaceuticals, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Arcturus Therapeutics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Alnylam Pharmaceuticals (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Vector-Based RNAi Sale, by Type, Application, End-users and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Vector-Based RNAi (Value)
      • 7.2.1. Global Vector-Based RNAi by: Type (Value)
        • 7.2.1.1. SiRNA Design
        • 7.2.1.2. SiRNA Vectors
        • 7.2.1.3. Custom siRNA Construction
      • 7.2.2. Global Vector-Based RNAi by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Ocular Disorders
        • 7.2.2.3. Hepatitis B and C
        • 7.2.2.4. Autoimmune Hepatitis
        • 7.2.2.5. Therapeutics
        • 7.2.2.6. Respiratory Disorders
        • 7.2.2.7. Neurological Disorders
        • 7.2.2.8. Other Therapeutics
      • 7.2.3. Global Vector-Based RNAi by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
      • 7.2.4. Global Vector-Based RNAi Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Vector-Based RNAi: by Type(USD Million)
  • Table 2. Vector-Based RNAi SiRNA Design , by Region USD Million (2015-2020)
  • Table 3. Vector-Based RNAi SiRNA Vectors , by Region USD Million (2015-2020)
  • Table 4. Vector-Based RNAi Custom siRNA Construction , by Region USD Million (2015-2020)
  • Table 5. Vector-Based RNAi: by Application(USD Million)
  • Table 6. Vector-Based RNAi Oncology , by Region USD Million (2015-2020)
  • Table 7. Vector-Based RNAi Ocular Disorders , by Region USD Million (2015-2020)
  • Table 8. Vector-Based RNAi Hepatitis B and C , by Region USD Million (2015-2020)
  • Table 9. Vector-Based RNAi Autoimmune Hepatitis , by Region USD Million (2015-2020)
  • Table 10. Vector-Based RNAi Therapeutics , by Region USD Million (2015-2020)
  • Table 11. Vector-Based RNAi Respiratory Disorders , by Region USD Million (2015-2020)
  • Table 12. Vector-Based RNAi Neurological Disorders , by Region USD Million (2015-2020)
  • Table 13. Vector-Based RNAi Other Therapeutics , by Region USD Million (2015-2020)
  • Table 14. Vector-Based RNAi: by End-users(USD Million)
  • Table 15. Vector-Based RNAi Hospitals , by Region USD Million (2015-2020)
  • Table 16. Vector-Based RNAi Specialty Clinics , by Region USD Million (2015-2020)
  • Table 17. South America Vector-Based RNAi, by Country USD Million (2015-2020)
  • Table 18. South America Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 19. South America Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 20. South America Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 21. Brazil Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 22. Brazil Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 23. Brazil Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 24. Argentina Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 25. Argentina Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 26. Argentina Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 27. Rest of South America Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 30. Asia Pacific Vector-Based RNAi, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 34. China Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 35. China Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 36. China Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 37. Japan Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 38. Japan Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 39. Japan Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 40. India Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 41. India Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 42. India Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 43. South Korea Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 44. South Korea Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 45. South Korea Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 46. Taiwan Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 47. Taiwan Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 48. Taiwan Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 49. Australia Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 50. Australia Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 51. Australia Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 55. Europe Vector-Based RNAi, by Country USD Million (2015-2020)
  • Table 56. Europe Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 57. Europe Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 58. Europe Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 59. Germany Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 60. Germany Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 61. Germany Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 62. France Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 63. France Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 64. France Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 65. Italy Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 66. Italy Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 67. Italy Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 68. United Kingdom Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 70. United Kingdom Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 71. Netherlands Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 72. Netherlands Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 73. Netherlands Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 74. Rest of Europe Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 77. MEA Vector-Based RNAi, by Country USD Million (2015-2020)
  • Table 78. MEA Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 79. MEA Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 80. MEA Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 81. Middle East Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 82. Middle East Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 83. Middle East Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 84. Africa Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 85. Africa Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 86. Africa Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 87. North America Vector-Based RNAi, by Country USD Million (2015-2020)
  • Table 88. North America Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 89. North America Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 90. North America Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 91. United States Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 92. United States Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 93. United States Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 94. Canada Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 95. Canada Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 96. Canada Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 97. Mexico Vector-Based RNAi, by Type USD Million (2015-2020)
  • Table 98. Mexico Vector-Based RNAi, by Application USD Million (2015-2020)
  • Table 99. Mexico Vector-Based RNAi, by End-users USD Million (2015-2020)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Vector-Based RNAi: by Type(USD Million)
  • Table 112. Vector-Based RNAi SiRNA Design , by Region USD Million (2021-2026)
  • Table 113. Vector-Based RNAi SiRNA Vectors , by Region USD Million (2021-2026)
  • Table 114. Vector-Based RNAi Custom siRNA Construction , by Region USD Million (2021-2026)
  • Table 115. Vector-Based RNAi: by Application(USD Million)
  • Table 116. Vector-Based RNAi Oncology , by Region USD Million (2021-2026)
  • Table 117. Vector-Based RNAi Ocular Disorders , by Region USD Million (2021-2026)
  • Table 118. Vector-Based RNAi Hepatitis B and C , by Region USD Million (2021-2026)
  • Table 119. Vector-Based RNAi Autoimmune Hepatitis , by Region USD Million (2021-2026)
  • Table 120. Vector-Based RNAi Therapeutics , by Region USD Million (2021-2026)
  • Table 121. Vector-Based RNAi Respiratory Disorders , by Region USD Million (2021-2026)
  • Table 122. Vector-Based RNAi Neurological Disorders , by Region USD Million (2021-2026)
  • Table 123. Vector-Based RNAi Other Therapeutics , by Region USD Million (2021-2026)
  • Table 124. Vector-Based RNAi: by End-users(USD Million)
  • Table 125. Vector-Based RNAi Hospitals , by Region USD Million (2021-2026)
  • Table 126. Vector-Based RNAi Specialty Clinics , by Region USD Million (2021-2026)
  • Table 127. South America Vector-Based RNAi, by Country USD Million (2021-2026)
  • Table 128. South America Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 129. South America Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 130. South America Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 131. Brazil Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 132. Brazil Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 133. Brazil Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 134. Argentina Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 135. Argentina Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 136. Argentina Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 137. Rest of South America Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 138. Rest of South America Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 139. Rest of South America Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 140. Asia Pacific Vector-Based RNAi, by Country USD Million (2021-2026)
  • Table 141. Asia Pacific Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 142. Asia Pacific Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 143. Asia Pacific Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 144. China Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 145. China Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 146. China Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 147. Japan Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 148. Japan Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 149. Japan Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 150. India Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 151. India Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 152. India Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 153. South Korea Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 154. South Korea Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 155. South Korea Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 156. Taiwan Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 157. Taiwan Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 158. Taiwan Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 159. Australia Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 160. Australia Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 161. Australia Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 165. Europe Vector-Based RNAi, by Country USD Million (2021-2026)
  • Table 166. Europe Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 167. Europe Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 168. Europe Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 169. Germany Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 170. Germany Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 171. Germany Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 172. France Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 173. France Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 174. France Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 175. Italy Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 176. Italy Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 177. Italy Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 178. United Kingdom Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 179. United Kingdom Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 180. United Kingdom Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 181. Netherlands Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 182. Netherlands Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 183. Netherlands Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 184. Rest of Europe Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 185. Rest of Europe Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 186. Rest of Europe Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 187. MEA Vector-Based RNAi, by Country USD Million (2021-2026)
  • Table 188. MEA Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 189. MEA Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 190. MEA Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 191. Middle East Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 192. Middle East Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 193. Middle East Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 194. Africa Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 195. Africa Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 196. Africa Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 197. North America Vector-Based RNAi, by Country USD Million (2021-2026)
  • Table 198. North America Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 199. North America Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 200. North America Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 201. United States Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 202. United States Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 203. United States Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 204. Canada Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 205. Canada Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 206. Canada Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 207. Mexico Vector-Based RNAi, by Type USD Million (2021-2026)
  • Table 208. Mexico Vector-Based RNAi, by Application USD Million (2021-2026)
  • Table 209. Mexico Vector-Based RNAi, by End-users USD Million (2021-2026)
  • Table 210. Research Programs/Design for This Report
  • Table 211. Key Data Information from Secondary Sources
  • Table 212. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Vector-Based RNAi: by Type USD Million (2015-2020)
  • Figure 5. Global Vector-Based RNAi: by Application USD Million (2015-2020)
  • Figure 6. Global Vector-Based RNAi: by End-users USD Million (2015-2020)
  • Figure 7. South America Vector-Based RNAi Share (%), by Country
  • Figure 8. Asia Pacific Vector-Based RNAi Share (%), by Country
  • Figure 9. Europe Vector-Based RNAi Share (%), by Country
  • Figure 10. MEA Vector-Based RNAi Share (%), by Country
  • Figure 11. North America Vector-Based RNAi Share (%), by Country
  • Figure 12. Global Vector-Based RNAi share by Players 2020 (%)
  • Figure 13. Global Vector-Based RNAi share by Players (Top 3) 2020(%)
  • Figure 14. Global Vector-Based RNAi share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Phio Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Phio Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Quark Pharmaceuticals, Inc. (Israel) Revenue, Net Income and Gross profit
  • Figure 21. Quark Pharmaceuticals, Inc. (Israel) Revenue: by Geography 2020
  • Figure 22. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 23. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 24. Silence Therapeutics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. Silence Therapeutics (United Kingdom) Revenue: by Geography 2020
  • Figure 26. Qiagen NV (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Qiagen NV (Germany) Revenue: by Geography 2020
  • Figure 28. Ionis Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 29. Ionis Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 30. Dicerna Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Dicerna Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 32. Arrowhead Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Arrowhead Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Arcturus Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 35. Arcturus Therapeutics (United States) Revenue: by Geography 2020
  • Figure 36. Alnylam Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 37. Alnylam Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 38. Global Vector-Based RNAi: by Type USD Million (2021-2026)
  • Figure 39. Global Vector-Based RNAi: by Application USD Million (2021-2026)
  • Figure 40. Global Vector-Based RNAi: by End-users USD Million (2021-2026)
  • Figure 41. South America Vector-Based RNAi Share (%), by Country
  • Figure 42. Asia Pacific Vector-Based RNAi Share (%), by Country
  • Figure 43. Europe Vector-Based RNAi Share (%), by Country
  • Figure 44. MEA Vector-Based RNAi Share (%), by Country
  • Figure 45. North America Vector-Based RNAi Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Merck & Co., Inc. (United States)
  • Phio Pharmaceuticals Inc. (United States)
  • Quark Pharmaceuticals, Inc. (Israel)
  • Thermo Fisher Scientific (United States)
  • Silence Therapeutics (United Kingdom)
  • Qiagen NV (Germany)
  • Ionis Pharmaceuticals (United States)
  • Dicerna Pharmaceuticals (United States)
  • Arrowhead Pharmaceuticals, Inc. (United States)
  • Arcturus Therapeutics (United States)
  • Alnylam Pharmaceuticals (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation